文献速递生殖医学

不明原因不孕夫妇宫腔内人工授精中促性腺激素与克罗米芬的成本效果分析

Gonadotrophins or clomiphene citrate in couples with unexplained infertility undergoing intrauterine insemination: a cost-effectiveness analysis.
PubMed 文献 · Reprod Biomed Online · 2019-09-16

本研究为一项在荷兰开展的多中心随机对照试验的成本效果分析,纳入738对不明原因不孕夫妇,随机接受促性腺激素(369对)或克罗米芬(369对)联合宫腔内人工授精(IUI)及严格取消标准下的卵巢刺激。结果显示,促性腺激素组每对夫妇平均费用为1534欧元,克罗米芬组为1067欧元(平均差468欧元,95%CI 464-472);持续妊娠率分别为31%和26%(相对风险1.16,95%CI 0.93-1.47)。促性腺激素每增加一例持续妊娠的增量成本效果比(ICER)为21,804欧元(95%CI 11,628-31,980),每增加一例活产的ICER为17,044欧元(95%CI 8,998-25,090)。结论认为,在严格取消标准下进行IUI时,促性腺激素较克罗米芬更昂贵,但未显著提高效果。

要点

  • 促性腺激素组每对夫妇平均费用1534欧元,克罗米芬组1067欧元,平均差468欧元(95%CI 464-472)。
  • 持续妊娠率促性腺激素组31% vs 克罗米芬组26%,相对风险1.16(95%CI 0.93-1.47)。
  • 促性腺激素每增加一例持续妊娠的ICER为21,804欧元(95%CI 11,628-31,980),每增加一例活产的ICER为17,044欧元(95%CI 8,998-25,090)。

核心结论

  • 在严格取消标准下进行IUI的不明原因不孕夫妇中,促性腺激素较克罗米芬更昂贵,但未显著更有效。

研究设计与样本

  • 一项随机对照试验的成本效果分析,2013年7月至2016年3月在荷兰多中心纳入738对夫妇,随机分配至促性腺激素组(369对)或克罗米芬组(369对),按意向治疗分析。

主要发现

  • 促性腺激素组每对夫妇平均费用1534欧元,克罗米芬组1067欧元,平均差468欧元(95%CI 464-472)。
  • 促性腺激素组持续妊娠率31%,克罗米芬组26%,相对风险1.16(95%CI 0.93-1.47)。
  • 促性腺激素每增加一例持续妊娠的ICER为21,804欧元(95%CI 11,628-31,980),每增加一例活产的ICER为17,044欧元(95%CI 8,998-25,090)。

临床怎么用

  • 在严格取消标准下进行IUI的不明原因不孕夫妇中,选择促性腺激素较克罗米芬增加费用而不显著提高持续妊娠或活产率。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: What is the cost-effectiveness of gonadotrophins compared with clomiphene citrate in couples with unexplained subfertility undergoing intrauterine insemination (IUI) with ovarian stimulation under strict cancellation criteria? DESIGN: A cost-effectiveness analysis alongside a randomized controlled trial (RCT). Between July 2013 and March 2016, 738 couples were randomized to gonadotrophins (369) or clomiphene citrate (369) in a multicentre RCT in the Netherlands. The direct medical costs of both strategies were compared. Direct medical costs included costs of medication, cycle monitoring, insemination and, if applicable, pregnancy monitoring. Non-parametric bootstrap resampling was used to investigate the effect of uncertainty in estimates. The cost-effectiveness analysis was performed according to intention-to-treat. The incremental cost-effectiveness ratio (ICER) between gonadotrophins and clomiphene citrate for ongoing pregnancy and live birth was assessed. RESULTS: The mean costs per couple were €1534 for gonadotrophins and €1067 for clomiphene citrate (mean difference of €468; 95% confidence interval [CI] €464-472). As ongoing pregnancy rates were 31% in women allocated to gonadotrophins and 26% in women allocated to clomiphene citrate (relative risk 1.16, 95% CI 0.93-1.47), the ICER was €21,804 (95% CI €11,628-31,980) per additional ongoing pregnancy with gonadotrophins and €17,044 (95% CI €8998-25,090) per additional live birth with gonadotrophins. CONCLUSIONS: Gonadotrophins are more expensive compared with clomiphene citrate in couples with unexplained subfertility undergoing IUI with adherence to strict cancellation criteria, without being significantly more effective.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Danhof NA, van Wely M, Repping S, et al. Gonadotrophins or clomiphene citrate in couples with unexplained infertility undergoing intrauterine insemination: a cost-effectiveness analysis. Reprod Biomed Online. 2019. PMID: 31787550. doi:10.1016/j.rbmo.2019.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。